One pioneer product invented by eTheRNA known as the “TriMix” mRNA adjuvant vaccine, which encodes CD70 to activate CD8+ T cells, CD40L to stimulate CD4+ T cells, and constitutively active TLR4 to promote antigen presentation in DCs [180], has been proven to be well tolerated and immunogenic in clinical trials against melanoma [181,182,183]. Here, CD8A is linked to melanoma.